Combination lab
Model what happens when peptides share a solution.
Pick up to six compounds and a solution pH. We compute each sequence's charge, isoelectric point and hydropathy, then flag predictable chemical interactions, complexation, aggregation, disulfide exchange and degradation hotspots. This is in-vitro chemistry, not a prediction of effects in the body.
Mix assessment
Overall
Weak case
Chemical compatibility
Compatible
Weakest evidence
Preclinical only
Chemical conflicts or preclinical-only evidence make outcomes highly uncertain.
Possible benefits (research rationale)
- +Complementary research areas: Tissue repair & healing (studied for wound, tendon and soft-tissue repair); Skin & extracellular matrix (studied for collagen, skin quality and ECM remodelling).
- +BPC-157: Proposed to promote angiogenesis and modulate nitric oxide and VEGF signalling, accelerating healing of tendon, ligament, muscle and gut tissue in animal injury models. No validated human receptor or pharmacokinetic profile has been published, and nearly all supportive data come from a small cluster of laboratories using rodent models.
- +GHK-Cu: Reported to modulate gene-expression networks involved in wound healing, collagen and elastin synthesis, antioxidant defence and inflammation. Most mechanistic work is gene-expression correlation analysis and topical skin work from a small set of investigators rather than controlled clinical trials.
Possible downsides
- −Tissue repair & healing: pro-angiogenic / growth-promoting signalling raises theoretical concerns where malignancy is present.
- −Skin & extracellular matrix: much of the evidence is cosmetic or manufacturer-funded.
- −BPC-157, GHK-Cu have no controlled human evidence, human effects alone are unknown, let alone in combination.
- −Not approved for this use: BPC-157, GHK-Cu. Research-grade products are unregulated and purity varies.
- −No study in the index tests this combination, so interactions, dosing and safety are unknown.
| Compound | Mass (Da) | Charge @ pH 7.4 | pI | GRAVY | Category |
|---|---|---|---|---|---|
| BPC-157 | 1420 | -2.1 | 3.9 | -0.69 | Tissue repair & healing |
| GHK-Cu | ≈340 Da | - | - | - | Skin & extracellular matrix |
Predicted chemical interactions
BPC-157 + GHK-Cu
- Sequence-level modelling unavailable. GHK-Cu contains non-standard residues, lipidation or an undisclosed sequence, so charge and stability cannot be computed reliably.
Mixture summary
- Summed mass
- 1420 Da
- Summed charge
- -2.1
- Same category
- No
Stability hotspots
- BPC-157: none flagged
- GHK-Cu: sequence not modelled
Published combination evidence
The index holds no peer-reviewed study testing this combination. Biological synergy, safety and dosing cannot be inferred from chemistry alone.
Educational model only. Values are computed from linear sequences (EMBOSS pKa set, Kyte–Doolittle scale) and ignore modifications, formulation and in-vivo metabolism. This is not medical, dosing or compounding advice, never combine or administer research compounds. See the full disclaimer.